Searched over 200M research papers for "rapamycin supplement"
10 papers analyzed
These studies suggest that rapamycin supplementation can improve arterial function, erectile function, peripheral nerve myelination, insulin sensitivity, renal damage, and reduce cardiomyocyte apoptosis, but its effects on lifespan and neuromuscular function are variable.
20 papers analyzed
Rapamycin, a potent inhibitor of the mammalian target of rapamycin (mTOR), has garnered significant attention for its potential therapeutic benefits across various health conditions. This article synthesizes recent research findings on the effects of rapamycin supplementation, focusing on its impact on aging, diabetes, cardiovascular health, and other conditions.
Research indicates that rapamycin supplementation can reverse age-related vascular dysfunction and oxidative stress. In aged mice, rapamycin improved glucose tolerance, reduced arterial stiffness, and normalized superoxide production and NADPH oxidase expression, thereby enhancing endothelium-dependent dilation (EDD). These findings suggest that rapamycin may mitigate some of the adverse vascular changes associated with aging.
The effects of rapamycin on longevity have also been studied in Drosophila melanogaster. Results show that the impact of rapamycin on lifespan is sex-, strain-, and solvent-dependent. While some strains exhibited increased longevity, others experienced a decrease, highlighting the complexity of rapamycin's effects on lifespan.
In a study on rats with streptozotocin-induced type 1 diabetes, rapamycin supplementation improved erectile function by promoting autophagy, reducing apoptosis, and ameliorating endothelial dysfunction and corporal fibrosis. This suggests that rapamycin could be a potential treatment for diabetes-induced erectile dysfunction (DMED).
Rapamycin has shown both positive and negative effects on type 2 diabetes (T2D). While it reduced weight gain, adiposity, and inflammation, it also exacerbated hyperglycemia and hypertriglyceridemia. However, co-treatment with metformin retained the benefits of rapamycin while mitigating its adverse effects, normalizing insulin sensitivity and reducing complications of metabolic syndrome.
In a rat model of chronic heart failure, rapamycin treatment improved cardiac function and inhibited cardiac remodeling. It reduced cardiomyocyte apoptosis and promoted autophagy by inhibiting the mTOR and endoplasmic reticulum (ER) stress pathways, suggesting a protective role in heart failure.
Rapamycin also benefits peripheral nerve myelination in neuropathic conditions such as Charcot-Marie-Tooth disease type 1A (CMT1A). Although it improved myelination, it did not enhance neuromuscular performance, indicating a differential response between nerve and muscle tissues.
In mice with systemic lupus erythematosus, rapamycin alleviated renal damage by improving immune response and function. It increased body weight, reduced immune complex deposition, and decreased levels of various autoantibodies, demonstrating its potential in managing autoimmune conditions.
Rapamycin has been shown to interfere with regulatory T cell homeostasis post-transplantation, leading to increased donor-specific antibodies (DSA) and vasculopathy. However, co-treatment with CTLA4-Ig corrected these adverse effects, suggesting a need for combination therapies to optimize outcomes.
Rapamycin supplementation exhibits a broad spectrum of effects across various health conditions, from improving vascular function and longevity to managing diabetes and autoimmune diseases. While its benefits are evident, the complexity of its impact necessitates careful consideration of dosage, combination therapies, and individual patient characteristics to maximize therapeutic outcomes.
Most relevant research papers on this topic